Skip to main content
  • Home
  • News
  • 2017
  • 06
  • Dr. Hamid Ghandehari is Awarded NIH STTR Phase II Grant

Dr. Hamid Ghandehari is Awarded NIH STTR Phase II Grant

Jun 27, 2017

Dr. Hamid Ghandehari is Awarded NIH STTR Phase II Grant

Congratulations to Dr. Hamid Ghandehari, Professor in the Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, Director of Utah Center for Nanomedicine, Co-Founder and Co-Director of the Nano Institute of Utah and Director of the University of Utah Nanotechnology Training Program for continuing his innovative research.

Dr. Ghandehari was awarded a NIH STTR Phase II grant in collaboration with a local company, TheraTarget, Inc. The project is "In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma". Total costs of the grant are $1,401,869, which ends August 2019.

Hamid Ghandehari